James E. Polli

9.7k total citations · 1 hit paper
198 papers, 7.0k citations indexed

About

James E. Polli is a scholar working on Oncology, Pharmaceutical Science and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, James E. Polli has authored 198 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 76 papers in Pharmaceutical Science and 66 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in James E. Polli's work include Drug Transport and Resistance Mechanisms (82 papers), Drug Solubulity and Delivery Systems (71 papers) and Analytical Methods in Pharmaceuticals (39 papers). James E. Polli is often cited by papers focused on Drug Transport and Resistance Mechanisms (82 papers), Drug Solubulity and Delivery Systems (71 papers) and Analytical Methods in Pharmaceuticals (39 papers). James E. Polli collaborates with scholars based in United States, Germany and Sweden. James E. Polli's co-authors include Bhagwant Rege, Lawrence X. Yu, Vinod P. Shah, Joseph P. Y. Kao, Anand Balakrishnan, Stephen W. Hoag, Mansoor A. Khan, Janet Woodcock, G. K. Raju and Sean Ekins and has published in prestigious journals such as Journal of Biological Chemistry, Neurology and Journal of Controlled Release.

In The Last Decade

James E. Polli

196 papers receiving 6.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Understanding Pharmaceutical Quality by Design

2014 918 citations Stephen W. Hoag, James E. Polli et al. The AAPS Journal profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
James E. Polli	2.6k	2.0k	1.5k	1.2k	837	198	7.0k
Peter Langguth	3.3k 1.3×	1.9k 0.9×	2.2k 1.5×	954 0.8×	1.0k 1.2×	271	9.1k
Arik Dahan	3.3k 1.3×	1.9k 0.9×	1.3k 0.9×	604 0.5×	945 1.1×	135	6.6k
Shinji Yamashita	2.9k 1.1×	1.6k 0.8×	1.4k 0.9×	665 0.6×	862 1.0×	167	5.8k
Pieter Annaert	1.9k 0.7×	1.9k 0.9×	1.3k 0.9×	1.4k 1.2×	1.1k 1.3×	237	7.6k
Bertil Abrahamsson	3.6k 1.4×	1.1k 0.5×	1.2k 0.8×	594 0.5×	982 1.2×	132	6.3k
Christel A. S. Bergström	2.8k 1.1×	1.3k 0.7×	1.3k 0.9×	620 0.5×	1.8k 2.2×	149	6.5k
René Holm	4.7k 1.8×	1.1k 0.5×	1.9k 1.3×	680 0.6×	1.9k 2.3×	266	8.3k
Marival Bermejo	1.8k 0.7×	1.1k 0.5×	1.0k 0.7×	414 0.4×	644 0.8×	143	4.6k
Christos Reppas	6.6k 2.5×	1.5k 0.7×	1.2k 0.8×	1.0k 0.9×	2.4k 2.8×	152	9.0k
Anette Müllertz	7.3k 2.8×	1.7k 0.8×	2.1k 1.4×	865 0.7×	2.1k 2.5×	274	11.2k

Countries citing papers authored by James E. Polli

Since Specialization

Citations

This map shows the geographic impact of James E. Polli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Polli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Polli more than expected).

Fields of papers citing papers by James E. Polli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Polli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Polli. The network helps show where James E. Polli may publish in the future.

Co-authorship network of co-authors of James E. Polli

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Polli. A scholar is included among the top collaborators of James E. Polli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Polli. James E. Polli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kane, Maureen A., et al.. (2025). In Vitro-In Vivo Correlation Of Amorphous Solid Dispersion Enabled Itraconazole Tablets. Pharmaceutical Research. 42(3). 485–502.

Polli, James E., et al.. (2025). Prediction of surfactant-mediated dissolution of poorly soluble drugs from drug powder. European Journal of Pharmaceutical Sciences. 208. 107052–107052. 1 indexed citations

Polli, James E., et al.. (2025). Impact of antioxidant addition on drug dissolution: Implications for NDSRI mitigation biowaivers. International Journal of Pharmaceutics. 681. 125806–125806. 3 indexed citations

Abrahamsson, Bertil, Naseem A. Charoo, Rodrigo Cristofoletti, et al.. (2024). Biowaiver monographs for immediate-release solid oral dosage forms: Voriconazole. Journal of Pharmaceutical Sciences. 114(2). 660–680. 4 indexed citations

Mackie, Claire, Sumit Arora, Paul Seo, et al.. (2024). Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report. Molecular Pharmaceutics. 21(5). 2065–2080. 24 indexed citations

Polli, James E., et al.. (2024). Prediction of Successful Amorphous Solid Dispersion Pairs through Liquid State Nuclear Magnetic Resonance. Molecular Pharmaceutics. 21(12). 6153–6165. 2 indexed citations

Babiskin, Andrew, Fang Wu, Ming‐Liang Tan, et al.. (2023). Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview. CPT Pharmacometrics & Systems Pharmacology. 12(5). 619–623. 10 indexed citations

Polli, James E., et al.. (2023). Validation of a method for itraconazole and major metabolite hydroxyitraconazole for LC-MS/MS analysis with application in a formulation clinical study. Journal of Pharmaceutical and Biomedical Analysis. 234. 115505–115505. 2 indexed citations

Gong, Yuqing, Miyoung Yoon, Hao Zhu, et al.. (2023). Establishing the suitability of model‐integrated evidence to demonstrate bioequivalence for long‐acting injectable and implantable drug products: Summary of workshop. CPT Pharmacometrics & Systems Pharmacology. 12(5). 624–630. 7 indexed citations

10.

Koziolek, Mirko, Patrick Augustijns, Rodrigo Cristofoletti, et al.. (2023). Challenges in Permeability Assessment for Oral Drug Product Development. Pharmaceutics. 15(10). 2397–2397. 12 indexed citations

11.

Taraban, Marc B., Dajun Sun, Jason D. Rodriguez, et al.. (2021). Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate. Molecular Pharmaceutics. 18(4). 1544–1557. 7 indexed citations

12.

Alonso, Antônio, et al.. (2020). Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. Pharmaceutics. 12(10). 988–988. 24 indexed citations

13.

Jiang, Xiaohui, et al.. (2020). Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy. Epilepsy & Behavior. 105. 106936–106936. 2 indexed citations

14.

Abrahamsson, Bertil, Rodrigo Cristofoletti, D.W. Groot, et al.. (2020). Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate. Journal of Pharmaceutical Sciences. 109(6). 1846–1862. 11 indexed citations

15.

Ting, Tricia Y., et al.. (2016). Release of levetiracetam from extended-release tablets that appear intact in patient stool. Seizure. 40. 7–9. 2 indexed citations

16.

Cai, Wendy, et al.. (2014). Lamotrigine, a Narrow Therapeutic Index Drug or Not? (P4.267). Neurology. 82(10_supplement). 1 indexed citations

17.

Polli, James E., et al.. (2014). Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver. International Journal of Pharmaceutics. 475(1-2). 597–604. 23 indexed citations

18.

Acharya, Chayan, et al.. (2009). Inhibition Requirements of the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT) Using Aminopiperidine Conjugates of glutamyl-Bile Acids. Pharmaceutical Research. 26(7). 1665–1678. 17 indexed citations

19.

Polli, James E.. (2008). In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms. The AAPS Journal. 10(2). 289–299. 113 indexed citations

20.

Joshi, Hemant, et al.. (2003). Characterization of Dexloxiglumide in vitro Biopharmaceutical Properties and Active Transport. Journal of Pharmaceutical Sciences. 92(10). 1968–1980. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact